Trial Profile
A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2015
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Pulmonary sarcoidosis
- Focus Therapeutic Use
- Sponsors Novartis
- 22 Sep 2015 Status changed from recruiting to discontinued, according to European Clinical Trials Database record.
- 15 Jul 2015 New trial record